Tarsus Pharmaceuticals Q2 sales beat estimates, lifts 2026 XDEMVY sales outlook
TARS•Analyst coverage
The current average analyst rating on the shares is strong buy, with 9 ratings of strong buy or buy, no hold ratings, and no sell or strong sell ratings.
Wall Street's median 12-month price target for Tarsus Pharmaceuticals, Inc. is $92.00, about 50.1% above its August 5 closing price of $61.29.
The stock recently traded at 44 times the next 12-month earnings, versus a P/E of 101 three months ago.
Drivers of sales growth
Tarsus said Q2 sales growth was driven by higher volume and improvements in the gross-to-net discount for XDEMVY.
The company also cited strong underlying demand, increased prescribing by eye care professionals, and expanded direct-to-consumer campaigns as supporting sales growth.
Higher SG&A expenses were primarily due to increased commercial and marketing costs, including DTC advertising and patient support functions.
Q2 sales beat estimates
Tarsus Pharmaceuticals said its second-quarter product sales rose over 69% year over year, beating analyst expectations.
The company reported second-quarter product sales of , compared with the consensus estimate of from eight analysts.
